| P/E (FY) | — | Sales (TTM) | $7.8M |
| Earnings (TTM) | -$4.5M | ROE | −80.93% |
| Net Margin | — | ROIC | — |
| Debt / Equity | — | TD / EBITDA | — |
| EPS Growth 3Y | — | Sales Growth 3Y | — |
| Market Cap | $6.1M | Trading Days | 3104 |
| 52W High | 5.80 |
| 52W Low | 1.16 |
| % Off High | −71.03% |
| YTD | −24.66% | 1Y | −68.08% |
| 3Y | −36.60% | 5Y | −90.02% |
| 10Y | −99.61% | Since incept. (ann.) | −46.28% |
| Ann. Volatility (1Y) | 86.21% | Ann. Volatility (3Y) | 90.45% |
| Sharpe (1Y) | −0.85 | Sharpe (3Y) | 0.26 |
| Max Drawdown (1Y) | −78.86% | Max Drawdown (3Y) | −88.12% |
| Beta (3Y, vs SPY) | 3.20 |
| Ticker | Name | Mkt cap | P/E |
|---|---|---|---|
| ACXP | Acurx Pharmaceuticals, Inc. | $6.1M | — |
| ALZN | Alzamend Neuro, Inc. | $6.3M | — |
| ADIL | ADIAL PHARMACEUTICALS, INC. | $6.3M | — |
| IMNN | Imunon, Inc. | $6.4M | — |
| CVKD | Cadrenal Therapeutics, Inc. | $5.8M | — |
| XBIO | Xenetic Biosciences, Inc. | $5.7M | — |
| KAPA | Kairos Pharma, LTD. | $6.6M | — |
| AEON | AEON Biopharma, Inc. | $6.7M | — |
| CURX | Curanex Pharmaceuticals Inc | $5.6M | — |
| INM | InMed Pharmaceuticals Inc. | $5.5M | — |
| RVPH | REVIVA PHARMACEUTICALS HOLDINGS, INC. |
| $5.5M |
| — |
| LIANY | LianBio | $5.4M | — |
